Company Overview
Inspire Medical Systems, Inc. operates as a medical technology company dedicated to the development and commercialization of minimally invasive solutions designed for patients suffering from obstructive sleep apnea in both the United States and international markets. The firm specializes in the Inspire system, which utilizes neurostimulation technology to address sleep disorders without the need for traditional surgical interventions or continuous positive airway pressure devices. This business model places the company firmly within the Healthcare sector, specifically targeting the Medical Devices industry where innovation and regulatory compliance are paramount. The organization employs a workforce of 1,333 individuals to support its global commercialization and research efforts. With a market capitalization of $1.51 billion and trailing twelve-month revenue of $911.98 million, the company demonstrates a significant scale within its niche. These valuation and revenue figures indicate that Inspire Medical Systems commands a substantial market position, suggesting it is a major player capable of sustaining extensive R&D programs and competitive marketing strategies in the sleep apnea treatment landscape.
Financial Health
Inspire Medical Systems, Inc. reported trailing twelve-month revenue of $911.98 million, generating net income of $145.42 million and an EBITDA of $64.91 million during the same period. The substantial gap between revenue and net income reveals a cost structure heavily influenced by high operating expenses, yet the company maintains profitability despite these costs. Free cash flow stands at $54.50 million, a metric that signifies the company possesses sufficient cash generation to cover capital expenditures and potentially fund future growth initiatives without relying solely on external financing. The company's balance sheet is characterized by a cash balance of $308.27 million against total debt of $32.16 million, illustrating a highly conservative financial stance with significant liquidity reserves. This conservative approach is further validated by a debt-to-equity ratio of 4.12, which, while indicating leverage, is offset by the massive cash hoard, effectively reducing net leverage risk. Additionally, a current ratio of 6.08 demonstrates exceptional short-term liquidity, indicating the firm holds more than six times the current assets necessary to meet its short-term liabilities. Return on equity is recorded at 19.8%, reflecting efficient capital utilization by management to generate shareholder value, while return on assets sits at 3.7%, showing how effectively the asset base supports overall earnings before interest and taxes.
Valuation Assessment
The stock currently exhibits a trailing P/E ratio of 10.65 compared to a forward P/E of 19.37, implying that the market expects earnings growth that will justify the higher future multiple relative to historical performance. The price-to-book ratio is 1.91, indicating that the market values the company at nearly double its book value, which suggests investors are pricing in intangible assets, growth potential, or brand strength beyond the tangible net asset base. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.66 and an EV/EBITDA of 18.68, suggesting the company trades at a premium relative to its sales and earnings power compared to lower-multiple peers. Regarding trading range, the 52-week high is $172.95 and the 52-week low is $50.50, providing a wide band of volatility within which the current share price fluctuates. The beta value of 0.78 indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting it may act as a defensive holding during periods of general equity market decline.
Growth & Income
Inspire Medical Systems, Inc. is currently experiencing robust expansion with revenue growth of 12.2% year-over-year and earnings growth of 308.4% year-over-year. The disparity between these two growth rates reveals that earnings are expanding at a velocity far exceeding revenue growth, which typically implies significant cost synergies, one-time gains, or a shift in product mix toward higher-margin offerings. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating a strategy to reinvest all generated earnings directly into research, development, and commercial expansion rather than distributing cash to shareholders. This reinvestment approach supports long-term growth objectives in a capital-intensive medical device environment where continuous innovation is required to maintain competitive advantage. Overall, the company presents a profile characterized by high earnings acceleration and a disciplined capital allocation strategy focused on organic growth within the obstructive sleep apnea therapeutic area.